CRC 02
Alternative Names: CRC-02Latest Information Update: 11 Dec 2023
At a glance
- Originator Curocell
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 11 Dec 2023 Preclinical trials in Multiple myeloma in South Korea (Parenteral), prior to December 2023 (Curocell pipeline, December 2023)
- 01 Feb 2021 Early research in Lymphoma in South Korea (Parenteral) before February 2021 (Curocell pipeline, February 2021)